2 / 22
Page 21
Notes:
allied
academies
Journal of Clinical and Experimental Toxicology | Volume: 3
February 21-22, 2019 | Paris, France
International Conference on
Environmental Toxicology and Pharmacology
Current stage and future perspective of nanoparticle for drug delivery in Brain Disorders
Ana Maria Buga
University of Medicine and Pharmacy of Craiova, Romania
C
entral nervous system (CNS) is a highly selective
environment that can prevent the access of many
molecules at this level. This property is crucial for the
integrity and function of CNS in normal condition but can
be detrimental for brain lesion therapy. Brain-blood barrier
(BBB) is a key structure involved in CNS selectivity that allows
passing only very small molecule or fat-soluble molecule
without transporter mechanisms. With ageing population
neurological disorders are the leading cause of disability
worldwide. Despite of new promising tools, there are no
effective therapeutic strategies and many of neurological
diseases are still untreatable.
In the last decade many strategies were performed in order
to increase the permeability of BBB for drugs or cells at the
brain lesion site, but many of these failed to be effective.
Current work is focused to design nanoparticle that can
incorporate a specific molecule or cells in order to increase
BBB permeability and to achieve therapeutic concentration
at lesion site.
However further investigation of safety and toxicity is needed
in order to achieve successful translation from animal model
to clinical application.
Speaker Biography
Ana Maria Buga is currently working in University of Medicine and Pharmacy of Craiova
in Romania. She won a prize for the best PhD Thesis, Medical Faculties of Greifswald,
Germany. She is a Board Member of the National Neuroscience Society, affiliated
FENS - IBRO, Eastern Europe. Her research of interest is identification of molecular and
cellular mechanisms leading to failure of axonal regeneration after a brain injury in
aged animals. She is an expertise on aged animal models of cerebral ischemia, genomic
and proteomic analysis, immunohistochemistry.
e:
anabuga07@gmail.comAna Maria Buga, J Clin Exp Tox, Volume 3
DOI: 10.4066/2630-4570-C1-006